Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNW79M
|
|||
| Drug Name |
ALXN1850
|
|||
| Drug Type |
Enzyme replacement
|
|||
| Indication | Hypophosphatasia [ICD-11: 5C64.3; ICD-10: E83.3; ICD-9: 275.3] | Phase 1 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alkaline phosphatase tissue-nonspecific (ALPL) | Target Info | Replacement | [2] |
| KEGG Pathway | Folate biosynthesis | |||
| Metabolic pathways | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathwhiz Pathway | Vitamin B6 Metabolism | |||
| WikiPathways | Endochondral Ossification | |||
| BDNF signaling pathway | ||||
| AGE/RAGE pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04980248) A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Alexion | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.